In Uncategorized, Xarelto Attorney

Xarelto (rivaroxaban) is a blood thinner manufactured by Bayer, primarily prescribed to prevent stroker and systemic embolism in patients with nonvalvular atrial fibrillation. It is also prescribed to prevent recurrence of deep-vein thrombosis and pulmonary embolism.

Xarelto was approved by by the FDA in 2011. Before its approval, the predominant blood-thinning drug was warfarin. Warfarin is an effective blood-thinner, though patients must undergo regular blood testing to ensure that the dosage is correct — that the blood is sufficiently thinned to help prevent strokes, but not too much.

When Xarelto came to the market, Bayer — the manufacturer — hired Janssen Pharmaceuticals to heavily market that Xarelto was superior to prior blood-thinners because it was a convenient once-daily dose that did not require blood monitoring. This marketing effort was apparently effective as Xarelto topped $1.5 billion in sales in 2014 alone.

But recent studies have shown that Xarelto is less effective than warfarin that has been accurately dosed through regular monitoring — yet Xarelto’s FDA approval was based on a standard of non-inferiority to other blood thinners.

Recent filings in federal court accuse Bayer of overstating the safety of Xarelto and negligently refusing to implement a commonly accepted method to reduce the serious side-effects of blood thinners, blood-monitoring, because it would harm Xarelto’s competitive advantage.

Plaintiffs in these filings have suffered a range of adverse bleeding events, including internal bleeding.

Recent Posts

Leave a Comment

Contact Us

We're not around right now. But you can send us an email and we'll get back to you, asap.

Not readable? Change text.

Start typing and press Enter to search